/>> The ICMR aims to launch a vaccine against COVID19 in elderly - TRENDING SAMACHAR

Breaking News

The ICMR aims to launch a vaccine against COVID19 in elderly

The ICMR aims to launch a  vaccine against COVID19 in elderly

The ICMR aims to launch a  vaccine against COVID19 in elderly

New Delhi India, 18 July: India Council of Medical Research (ICMR) to conduct a study to evaluate the effectiveness of BCG vaccination in preventing morbidity and mortality due to COVID-19 in the elderly between 60 and 95 Is ready. Age of living in COVID-19 hotspots in India.
The study will be conducted in six states (sites) of the country - Tamil Nadu, Maharashtra, Gujarat, Madhya Pradesh, Rajasthan and Delhi.

ICMR's National Institute for Research in Tuberculosis (NIRT) in Chennai is moving towards the study. In Tamil Nadu, the study will be conducted in collaboration with the Greater Chennai Corporation and the state's Department of Public Health.

"The study will document whether the BCG vaccine can prevent the occurrence of SARS-CoV-2 infection and its progression and death associated with COVID-19 among elderly individuals. The study used the same BCG vaccine Newborns are given as a part. National Immunization Program for more than 50 years in this country, "Dr. Subhash Babu, Scientific Director of National Research Institute in Tuberculosis.

According to the ICMR scientist, BCG is a vaccine against tuberculosis, which has protective non-specific effects against other respiratory tract infections in in vitro and in-vivo studies, and significant decreases in morbidity and mortality have been reported. .

"Hypothesis to reduce antivirals in experimental models, based on the ability of BCG to reduce the incidence of respiratory tract infections in children and adults; and to reduce viremia in an experimental human model of viral infection." Is that BCG vaccination will partially protect. Against high-risk mortality, elderly individuals, "the scientist said.
He points out that there are several clinical trials using the BCG vaccine already undergoing an elderly population worldwide.

"We have to evaluate the effectiveness of BCG vaccination in terms of reduction in the incidence of other respiratory-related illnesses, reduction in the cumulative incidence of hospital admission and intensive care admission, to determine congenital and adaptive immune responses, IgM, IgG and IgA . " As regards the risk or protection against SARS-C22 in a subset of individuals to measure the antibody titers generated by BCG vaccination (both total and SARS-Cov2 specific) and the biomarker induced by BCS vaccination, "Dr. Added Babu. "

The sample size methodology of the study is 1450 healthy individuals between the ages of 60 –95 years will receive BCG vaccination, while 725 individuals will be in control (without vaccination) who will be vaccinated after six months. Participants aged 60 - 80 are elderly populations living in red and orange areas (hotspots) for SARS-C22 infection.

Participants will be given a single dose of 0.1 ml BCG vaccine given intradermally. Elderly individuals are not vaccinated from the same hotspot area or neighboring hotspot ward areas that would be considered controls.

Apart from Chennai's NIRT site, there are five other centers, National Institute of Occupational Health, Ahmedabad in Gujarat, National Research Institute in Environmental Health in Bhopal in Madhya Pradesh, GS Medical College and KEM Hospital in Mumbai Maharashtra, National Implementation Research Institute, Jodhpur and Non-communicable diseases in AIIMS, New Delhi


No comments